UPCC 45419: Phase I Study of Tasquinimod Alone | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase 1

54 participants needed

1 Location

Brief description of study

The research study is being conducted to understand the effects of tasquinimod, an experimental medication, on patients with myeloma. Eligibile subject have multiple myeloma that has been previously treated and is now in need of additional treatment. Part 1 of this study evaluates tasquinimod alone. Part 2 of this study evaluates tasquinimod in combination with a standard myeloma treatment regimen known as IRd (including ixazomib, lenalidomide, and dexamethasone).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 09 Apr 2021. Study ID: 842603

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

UPCC 45419: Phase I Study of Tasquinimod Alone and in Combination with Standard Therapy for Relapsed or Refractory Myeloma

Brief description of study

Eligibility of study

Find a site